RICHARD C. MULLIGAN

Corporate Board Profile

Tech Score: 0/100

Bausch Health Companies Inc.

Filing Date	Source Excerpt
2022-05-02	Dr. Mulligan will serve as a director of the Company and the Chairperson of the Science and Technology Committee, effective upon the completion of the B+L IPO. ... 2021 Meeting Attendance: Not applicable.
2023-04-06	Dr. Mulligan has served on the Board since May 2022. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. Dr. Mulligan also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, Inc. a public biotechnology company, and a director of Biogen Inc., a public biotechnology company. Prior to Harvard, Dr. Mulligan was a professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and chief scientific officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was a founding partner of Sarissa Capital Management LP from 2013 to 2016 and from March 2017 to October 2018 served as Portfolio Manager at Icahn Capital LP. He was named a MacArthur Foundation Fellow in 1981. Qualifications: The Board has determined that Dr. Mulligan’s extensive experience in the biotechnology and life sciences industries and international reputation in academia qualifies him to serve as a member of the Board and the committees on which he serves.

Filing Date

Source Excerpt

2022-05-02

Dr. Mulligan will serve as a director of the Company and the Chairperson of the Science and Technology Committee, effective upon the completion of the B+L IPO. ... 2021 Meeting Attendance: Not applicable.

2023-04-06

Dr. Mulligan has served on the Board since May 2022. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. Dr. Mulligan also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, Inc. a public biotechnology company, and a director of Biogen Inc., a public biotechnology company. Prior to Harvard, Dr. Mulligan was a professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and chief scientific officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was a founding partner of Sarissa Capital Management LP from 2013 to 2016 and from March 2017 to October 2018 served as Portfolio Manager at Icahn Capital LP. He was named a MacArthur Foundation Fellow in 1981. Qualifications: The Board has determined that Dr. Mulligan’s extensive experience in the biotechnology and life sciences industries and international reputation in academia qualifies him to serve as a member of the Board and the committees on which he serves.

ENZON PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2009-04-13	Richard C. Mulligan, Ph.D., is the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative... The Board of Directors recommends a vote FOR Professor Mulligan as Class I Director (Proposal No. 1).
2010-06-10	Richard C. Mulligan, Ph.D. has served as a director since May 2009. Professor Mulligan is the Mallinckrodt Professor of Genetics at Harvard Medical School. The Governance and Nominating Committee currently consists of Mr. Micati (Chairman), Professor Mulligan and Messrs. Salisbury and LeBuhn. The Executive Committee consists of Dr. Denner (Chairman), Professor Mulligan and Mr. Classon.
2011-04-08	Richard C. Mulligan, Ph.D. has served as a director since May 2009 and Vice-Chairman of the Company 27s Board of Directors since March 2011. Professor Mulligan has been the Mallinckrodt Professor of Genetics at Harvard Medical School...Professor Mulligan 27s deep knowledge in the genetics field provides the Board with an important understanding...The Board has nominated and recommends that the stockholders elect Richard C. Mulligan...Vice-Chairman of the Board...Age 56...Total Director Compensation 210,012.
2012-04-06	Richard C. Mulligan has served as a director since May 2009 and Vice-Chairman of the Company 27s Board of Directors since March 2011...Professor Mulligan has been associated with a number of biotechnology companies...DIRECTOR COMPENSATION FOR FISCAL YEAR ENDED DECEMBER 31, 2011: Richard C. Mulligan Fees Earned or Paid in Cash ($) 75,750, Stock Awards ($) 131,257, Option Awards ($) 75,003, Total ($) 282,010.
2013-10-11	Dr. Denner, who has served as the Chairman of the Board since July 2009, and Professor Mulligan, who has served as the Vice-Chairman of the Board since March 2011, will not stand for re-election at the 2013 Annual Meeting. ... The Governance and Nominating Committee currently consists of Professor Mulligan (Chairman) and Dr. Denner.

Data sourced from SEC filings. Last updated: 2026-02-03